RPC reports four SPC decisions

In case you missed it, the recently-published August 2013 issue of the Reports of Patent, Design and Trade Mark Cases (RPC), produced on behalf of the UK's Intellectual Property Office by Oxford University Press, was entirely dedicated to reports of cases involving SPCs.  The cases are:

* Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents (Court of Justice of the European Union)

* Actavis Group PTC EHF v Sanofi (Patents Court, England and Wales)

* AstraZeneca AB v Comptroller-General of Patents (Patents Court, England and Wales)

* GlaxoSmithKline Biologicals SA v Comptroller-General of Patents (Patents Court, England and Wales).

The RPC is an official law report, published since 1884 and suitable for citation in UK litigation.

Official UK patent law reports focus on SPCs

Issue 2 (February 2010) of volume 127 of the Reports of Patent, Design and Trade Mark Cases (RPC), published for the Intellectual Property Office of the UK by Oxford University Press, contains official reports of four British decisions concerning SPCs. They are

* Merck & Co.'s SPC Extension Application (IPO, 6 February 2009, noted on The SPC Blog here);
* E. I. du Pont de Nemours & Co.'s SPC Extension Application (IPO, 9
April 2009, noted by The SPC Blog here);
* E. I. du Pont de Nemours & Co. v Intellectual Property Office
(Patents Court, 22 May 2009, noted by The SPC Blog here);
* E. I. du Pont de Nemours & Co. v Intellectual Property Office (Court of Appeal, 17 September 2009, noted on The SPC Blog here) .